$ORMP News

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

ORMP: View Inclusion in Russell Indexes as Positive That Could Raise Awareness in Investment Community

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

ORMP: Strategically Acquiring Interests in Medtech & Technology Companies

Oramed: Q4 Earnings Snapshot

Lifeward Successfully Closes on Strategic Partnership with Oramed

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company

Oramed Pharma Receives $18M Payment From Scilex Holdings, Representing $118M Total Returns On $99.5M Investment; Oramed Retains $39M Outstanding debt, Convertible Debt, Warrants, and Ongoing Royalty Interest

Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback

There Are Some Holes In Oramed Pharmaceuticals' (NASDAQ:ORMP) Solid Earnings Release

ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS

Reported November 13, 2025: Oramed Pharmaceuticals Q3 EPS $1.26 Beats $(0.08) Estimate, Sales $2.000M

Oramed: Q3 Earnings Snapshot

The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable

Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives

Oramed Advances Oral Insulin Program Independently; Announces Launch Of New U.S. Trial; Company Reaffirms Commitment To Rewarding Shareholders, Including Plans For One-Time Dividend

Oramed Advances Oral Insulin Program Independently; Announces Launch Of New U.S. Trial; Company Reaffirms Commitment To Rewarding Shareholders, Including Plans For One-Time Dividend

Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase

Oramed: Q2 Earnings Snapshot